Antidote
JANUARY 17, 2023
Hemophilia is a disease in which the blood does not clot properly. It is rare and typically hereditary, often leading to spontaneous or excessive bleeding, especially following injuries or surgery, and internal bleeding can be a major risk factor. Below, we’re exploring a few hemophilia facts many people may not know.
Drug Channels
JANUARY 17, 2023
Consolidation has brought together large, economically significant insurer/PBM/specialty pharmacy/provider organizations within U.S. drug channels. At least half of all U.S. healthcare spending flows through these seven familiar entities: Blue Cross Blue Shield, Centene, Cigna, CVS Health, Elevance Health, Humana, and United Health Group. In the brief video clip below, I review these businesses and offer some thoughts on their positioning for 2023.
Drug Patent Watch
JANUARY 16, 2023
This chart shows the drugs with the most patents in Malaysia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Malaysia? appeared first on DrugPatentWatch - Make Better Decisions.
Crucial Data Solutions
JANUARY 19, 2023
Demystifying and providing a solution for EHR to EDC interoperability has been a mission for CDS for the past four years. In this blog post, we break down various interoperability challenges and how the architecture of your eClinical software can be a game-changer. The post Making Data Exchange Feel Easy – Simplifying the Data Journey from EHR to EDC appeared first on Crucial Data Solutions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Antidote
JANUARY 18, 2023
National Glaucoma Awareness Month is a campaign aimed at increasing awareness around glaucoma, a leading cause of vision loss and blindness with no early warning signs.
Drug Channels
JANUARY 20, 2023
Today’s blog post comes from Andrew Duncan, Vice President of Business Operations and Analytics at PHIL. Andrew discusses how manufacturers can use data-driven strategy to understand utilization, increase patient access and adherence, and optimize gross-to-net. Click here to learn more about PHIL’s access and commercialization solutions. Read on for Andrew’s insights.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Predictive Oncology
JANUARY 19, 2023
Predictive Oncology CEO Raymond Vennare and Dr. Robert Murphy, an inventor of the engine behind our artificial intelligence (AI) platform and new member of our Scientific Advisory Board, were featured in an interview with Natalie Stoberman from Proactive. They discuss the impact that Predictive Oncology has in defining an entirely new category of oncology drug discovery.
BMG Labtech
JANUARY 18, 2023
G protein-coupled receptors (GPCRs) are highly sophisticated detection molecules that can respond to signals as diverse as a photon or a hormone. They are as old as the first multicellular organisms that appeared on the Earth around 600 million years ago. And if you need to take an FDA-approved drug, there’s around a one in three chance that it’s a drug that targets a GPCR.
Molecular Design
JANUARY 19, 2023
> I last posted on Covid-19 early in 2021 and quite a lot has happened since then. Specifically, a number of vaccines are now available (I received my first dose of AstraZeneca CoviShield in May 2021 while still stranded in Trinidad) and paxlovid has been approved for use as a Covid-19 treatment (Derek describes his experiences taking paxlovid in this post ).
Drug Patent Watch
JANUARY 20, 2023
Annual Drug Patent Expirations for CARNEXIV Carnexiv is a drug marketed by Lundbeck Pharms Llc and is included in one NDA. It is available from one supplier. There are six… The post New patent for Lundbeck Pharms drug CARNEXIV appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The Premier Consulting Blog
JANUARY 17, 2023
The Pediatric Research Equity Act (PREA) was signed into law in 2003 to increase pediatric use information in product labeling and close knowledge gaps regarding the safety, efficacy, and appropriate dosing of drugs to treat children. PREA requires new drug applications (NDAs) and biologics license applications (BLAs) for a new active ingredient, indication, dosage form, dosing regimen, or route of administration to contain a pediatric assessment, unless the applicant obtains a waiver or deferra
Molecule Blog
JANUARY 18, 2023
IP-NFTs are non fungible tokens that represent legally binding intellectual property (IP) currently being used within decentralized science ( DeSci ). Here, we outline their inner workings and how you could utilize their metadata schema, data layer and smart contract methods to create your own intellectual property representation on EVM based blockchains.
Reprocell
JANUARY 18, 2023
Today, clinical trials are conducted to aid our understanding of, and to assess new treatments for, medical conditions or disorders that affect the human population. The plethora of investigative research initiated following the emergence of the coronavirus, SARS-CoV-2, in 2019 and the resultant development, and worldwide roll out, of a life-saving vaccine is one example of our current global clinical trial landscape.
Drug Patent Watch
JANUARY 19, 2023
Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The protection granted to orphan drugs is quite strong. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Cytel
JANUARY 17, 2023
When it comes to rare diseases, a handful of major challenges to drug development arise. Bayesians strategies have become a viable option, however, in overcoming some of the major obstacles faced by clinical trial sponsors in these areas.
Labcorp Drug Development
JANUARY 17, 2023
Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies … The post 4 emerging trends to watch in immunotherapy clinical trials appeared first on Insights From Our Labs to Yours.
Sygnature Discovery
JANUARY 17, 2023
Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. Sygnature Discovery’s acquisition of SB Drug Discovery This transaction will offer a strategic advantage for both companies, to enable further expansion of the businesses and their capabilities, and forms
Drug Patent Watch
JANUARY 19, 2023
Annual Drug Patent Expirations for AMELUZ Ameluz is a drug marketed by Biofrontera and is included in one NDA. It is available from one supplier. There is one patent protecting… The post New patent for Biofrontera drug AMELUZ appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Dark Matter Blog
JANUARY 16, 2023
We are moving rapidly toward escape velocity in our RNA expedition at Arrakis. We want to mark this progress with some updates and perspectives in the Dark Matter blog. In the months ahead, we are rolling out a series of posts called “Fearlessly Forward” to bring you up to speed on how we’ve moved forward in our expedition. (We’ve been called crazy more than a few times, but we think a better word for Arrakeens is fearless.
DrugBank
JANUARY 17, 2023
Most of us know that without high quality data we can be left making assumptions that result in flawed research, bad decisions, and worse health outcomes. But knowing that we need quality data isn’t enough if we also don’t know what quality looks like. It can be tough to define quality in a succinct way because the metrics for success are so dependent on who is using the data and what they’re using it for.
New Drug Approvals
JANUARY 16, 2023
‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. Feeling great to be selected in the ‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. It is an online campaign to honour inspiring personalities and feature them in the upcoming edition of the top news sites, including – Deccan Chronicle/Asian Age/Deccan Herald, ANI, Zee5, Latestly, Lokmat Times, DailyHunt, Google News, JioNews, MSN and 70+ s
Drug Patent Watch
JANUARY 18, 2023
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Germany. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Germany? appeared first on DrugPatentWatch - Make Better Decisions.
Advarra
JANUARY 17, 2023
A highly valuable tool for research staff, electronic consent (eConsent) can simplify the consenting process for both staff and participants. Used effectively, eConsent can increase consenting quality while reducing audit findings at sites. As the industry continues to shift from studies conducted exclusively in person to more convenient hybrid formats, eConsent can be very useful. .
Eye on FDA
JANUARY 16, 2023
Through its Human Drugs Advisory Committee process FDA has a vast array of outside experts to consult on matters related to product approval as well as questions about policy or safety issues concerning approved products. The mechanism provides an open and transparent process whereby people can see and hear the deliberations and have input during open public comment as well as through a docket established for that purpose.
Conversations in Drug Development Trends
JANUARY 17, 2023
Ryan Gladden, our colleague and Black, Indigenous, People of Color (BIPOC) Employee Resource Group (ERG) member, shared his reflections on MLK Day. The post Reflections on Martin Luther King Jr. Day 2023 appeared first on Worldwide Clinical Trials.
Drug Patent Watch
JANUARY 18, 2023
Annual Drug Patent Expirations for GENOSYL Genosyl is a drug marketed by Vero Biotech and is included in one NDA. It is available from one supplier. There are twenty-two patents… The post New patent for Vero Biotech drug GENOSYL appeared first on DrugPatentWatch - Make Better Decisions.
Reprocell
JANUARY 16, 2023
Isolated blood vessels have been used for over a century to measure vascular contractility ex vivo , and rat aorta is commonly used due to its affordability and scalability. 1,2 However, species differences can impact the clinical translatability of animal tissues. In this article, we will explore how isolated blood vessels can be used to determine drug mechanisms ex vivo and how results can vary based on the type of tissue used.
Cytel
JANUARY 20, 2023
A small biotech’s conventional carcinoma trial design was too expensive to implement and did not offer the opportunity to stage-gate the funding.
Antidote
JANUARY 19, 2023
Oftentimes, clinical trial enrollment statistics paint a grim picture of the medical research landscape.
Drug Patent Watch
JANUARY 18, 2023
Annual Drug Patent Expirations for OPZELURA Opzelura is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are eleven patents… The post New patent for Incyte Corp drug OPZELURA appeared first on DrugPatentWatch - Make Better Decisions.
Dark Matter Blog
JANUARY 16, 2023
The post <span>Video:</span> Fearlessly Forward appeared first on Arrakis Therapeutics.
Precision for Medicine
JANUARY 20, 2023
Precision for Medicine will be exhibiting at BioTrinity in London. Stop by our booth to meet the team or schedule a meeting here. BioTrinity is a must attend London conference, that supports engagement across the life sciences industry. The post BioTrinity (April 25-26) appeared first on Precision For Medicine.
LifeSciVC
JANUARY 18, 2023
By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC Earlier this month, I attended the J.P. Morgan 41 st annual Healthcare Conference in San Francisco after a two-year hiatus. Despite the torrential rain and long flight, it was an energizing experience and a reminder of the glue that holds our industry together during tough times –the interpersonal connections and relationships.
Expert insights. Personalized for you.
98 
Let's personalize your content